Rangeley Capital’s ESSA Pharma EPIX Stock Holding History

Rangeley Capital’s Portfolio EPIX Stock Details EPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-170,000	Closed	-$289K	–	132
2025 Q2	$289K	Buy	+170,000	New	+$287K	0.34%	42

Other funds holding EPIX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Rangeley Capital's EPIX Position: Q3 2025 in Review

Rangeley Capital sold out of ESSA Pharma (EPIX) in Q3 2025, closing a stake of 170,000 shares — an estimated $289K sold.

Rangeley Capital first reported a position in EPIX in Q2 2025 and held it in 1 quarter. The position peaked at $289K in Q2 2025. 32 funds tracked by Wall St. Rank hold EPIX as of Q3 2025.

Rangeley Capital reported no remaining ESSA Pharma position as of Q3 2025 after selling out during the quarter.
Rangeley Capital sold 170,000 ESSA Pharma shares in Q3 2025, an estimated $289K.
Rangeley Capital first reported a position in ESSA Pharma in Q2 2025 and held it in 1 quarter.
Rangeley Capital's ESSA Pharma position peaked at $289K in Q2 2025.
32 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2025.

Based on Rangeley Capital's 13F filing for Q3 2025, filed 14 Nov 2025.